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SYSTEMATIC REVIEW AND META-ANALYSIS
Association of Isolated Coronary 
Microvascular Dysfunction With Mortality 
and Major Adverse Cardiac Events: A 
Systematic Review and Meta- Analysis of 
Aggregate Data
Mark A. Gdowski, MD; Venkatesh L. Murthy, MD, PhD; Michelle Doering, MLS; Andrea G. Monroy-Gonzalez, MD;  
Riemer Slart, MD, PhD; David L. Brown , MD
BACKGROUND: The impact of coronary microvascular dysfunction (CMD), as diagnosed by reduced coronary flow reserve, on 
the outcomes of patients with symptoms of myocardial ischemia and nonobstructive coronary artery disease is poorly under-
stood. We performed a systematic review and meta- analysis of observational studies to determine the association of CMD 
with outcomes.
METHODS AND RESULTS: We searched online databases for studies where coronary flow reserve was measured invasively or 
noninvasively, clinical events were recorded after determination of coronary flow reserve, and the frequency of those events 
was reported for patients with and without CMD. The primary outcome was all- cause mortality. The secondary outcome was 
major adverse cardiac events, including cardiac or cardiovascular death, nonfatal myocardial infarction, cardiac hospitaliza-
tion, or coronary revascularization. Estimates of effect were calculated from crude event rates with a random- effects model. 
There were 122 deaths in the 4661 patients without CMD (2.6%) and 183 deaths in the 1970 patients with CMD (9.3%). The 
odds ratio for mortality in patients with CMD compared with those without CMD was 3.93 (95% CI, 2.91–5.30; P<0.001). There 
were 167 major adverse cardiac events in the 3742 patients without CMD (4.5%) and 245 events in the 1447 patients with CMD 
(16.9%). The odds ratio for major adverse cardiac events in patients with CMD compared with those without CMD was 5.16 
(95% CI, 2.81–9.47; P<0.001).
CONCLUSIONS: CMD is associated with a nearly 4- fold increase in mortality and a 5- fold increase in major adverse cardiac 
events. Future studies are needed to identify effective strategies to diagnose and treat CMD.
Key Words: coronary flow reserve ■ coronary microvascular dysfunction ■ meta-analysis ■ outcomes
Chest pain is among the most common symp-toms evaluated in emergency departments and outpatient clinical settings. Although the dif-
ferential diagnosis is extensive, most evaluations of 
adults with risk factors for cardiovascular disease 
focus on the diagnosis of obstructive atherosclero-
sis of the epicardial coronary arteries, which is often 
considered the leading cause of myocardial ischemia 
and the primary driver of adverse outcomes. However, 
patients presenting with chest pain and found not to 
have obstructive coronary artery disease (CAD) on 
coronary angiography are increasingly recognized.1–3 
It is estimated that 3 to 4 million men and women 
in the United States have symptoms of myocardial 
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ischemia with no obstructive CAD.4,5 This population 
of patients has an elevated risk of mortality and major 
adverse cardiac events (MACE).2 One potential cause 
of angina without obstructive CAD is coronary micro-
vascular dysfunction (CMD), a disorder affecting the 
structure and/or function of the coronary microcir-
culation, resulting in reduced coronary flow reserve 
(CFR). CMD is associated with known cardiovascu-
lar risk factors, including hypertension,6,7 diabetes 
mellitus,8–10 hypercholesteremia,11 and smoking.12–15 
However, only ≈17% of variance in CFR is explained 
by traditional risk factors and <1% is explained by 
sex.16 Camici and Crea classified CMD into 4 main 
types based on their different pathophysiological 
characteristics: type 1, CMD in the absence of myo-
cardial disease and obstructive CAD; type 2, CMD in 
myocardial disease; type 3, CMD in obstructive CAD; 
and type 4, iatrogenic CMD.3
In the absence of obstructive CAD, CFR, the ratio of 
coronary flow achieved at maximal coronary vasodila-
tion/flow under baseline conditions, reflects coronary 
microvascular function; an abnormally reduced CFR 
indicates CMD.3 CFR can be measured invasively as 
an adjunct to coronary angiography or noninvasively, 
using positron emission tomography (PET) or trans-
thoracic Doppler echocardiography of the left anterior 
descending coronary artery.17
Patients presenting with angina and found not to 
have obstructive CAD are often given reassurance 
that their symptoms are noncardiac18 and do not place 
them at an increased risk of adverse events. However, 
these patients, if found to have CMD on the basis of 
an abnormal CFR, have been shown in several single- 
center studies to have increased rates of all- cause or 
cardiac mortality and MACE. To better understand the 
impact of isolated CMD on outcomes, we performed 
a systematic review and meta- analysis of published 
studies to determine the association of CMD with mor-
tality and MACE in type 1 patients without obstructive 
CAD or other cardiac pathological characteristics.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request.
Protocol and Registration
We conducted a systematic review and meta- analysis 
of published studies, according to the Meta- Analysis 
of Observational Studies in Epidemiology guide-
lines.19 This study was registered at the International 
Prospective Register of Systematic Reviews 
(CRD42019117036).
Information Sources
The search was implemented in April 2019 by a 
medical librarian (M.D.) in Ovid Medline 1946- , 
Embase.com 1947- , Scopus 1960- , Cochrane 
Central Register of Controlled Trials, Database of 
Abstracts of Reviews of Effects, Cochrane Database 
of Systematic Reviews, and Clinicaltrials.gov using 
controlled vocabulary and keywords for the follow-
ing: coronary flow reserve, measurement, diagnostic 
imaging, thermodilution, follow- up, hospitalization, 
MACE, and death. Articles were restricted to the 
English language and published literature. The full 
search strategy is provided in Data S1.
Study Eligibility
Studies were included in the meta- analysis if CFR 
was prospectively measured either invasively or 
CLINICAL PERSPECTIVE
What Is New?
• In this systematic review and meta-analysis 
of >5000 patients with suspected ischemia, 
nonobstructive epicardial coronary artery dis-
ease on coronary angiography, or absence of 
myocardial ischemia on stress testing, ≈30% 
of patients, equally divided between men and 
women, had abnormally reduced coronary flow 
reserve diagnostic of coronary microvascular 
dysfunction.
• In these patients, we observed a nearly 4-fold 
higher mortality and a 5-fold increase in major 
adverse cardiac events among individuals with 
coronary microvascular dysfunction compared 
with those with normal coronary microvascular 
function.
What Are the Clinical Implications?
• These results support the need to integrate the 
totality of the coronary circulation, both macro-
vascular and microvascular, when conceptu-
alizing the pathophysiological characteristics, 
treatment, and prognosis of patients with symp-
toms of ischemic heart disease.
Nonstandard Abbreviations and Acronyms
CFR coronary flow reserve
CMD coronary microvascular dysfunction
MACE major adverse cardiac event(s)
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noninvasively; clinical events, including death, cardio-
vascular death, cardiac death, myocardial infarction, 
hospital admission, and/or coronary revasculariza-
tion, that occurred after determination of CFR were 
recorded and the frequency of those events were 
compared between patients with normal and abnor-
mal CFR. The definition of abnormal CFR was that 
used in each study and had to be defined prospec-
tively. To limit the study population to isolated or type 
1 CMD, only studies of patients with nonobstruc-
tive CAD on invasive coronary angiography (or who 
had a negative stress test for myocardial ischemia if 
coronary angiography was not performed) were in-
cluded and studies of patients with a history of heart 
transplantation, cardiomyopathy, or aortic stenosis 
were excluded.
Study Selection
The study selection process is presented in Figure 1. 
Two independent reviewers (M.A.G., D.L.B.) initially 
screened the retrieved citations for potential relevance 
by assessment of the title and abstract to determine 
eligibility. The full text of the article was reviewed if the 
content was not clear from the abstract. Agreement 
was 100%. If a study was potentially relevant, the full 
report was assessed using the selection criteria for in-
clusion. In cases where there was overlap of the study 
Figure 1. Flow diagram of included studies.
CAD indicates coronary artery disease; CFR, coronary flow reserve; and MI, myocardial infarction.
6532 Total number of records 
idenfied through database search
2919 Duplicates removed
3613 Total number of 
arcles screened
3543 Arcles excluded based on tle and 
abstract
70 Full text arcles retrieved for 
detailed assessment
59 Arcles excluded
16  Incorrect study design or endpoint
7 Obstrucve CAD not defined
9 Abnormal CFR not prospecvely defined
9 Obstrucve CAD or recent MI included
18 Duplicate populaon 
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population or enrollment period in articles published 
by the same investigators, the article with the greatest 
number of patients was used for the analysis.
Data Extraction
The following information was extracted from each ar-
ticle: editorial information (lead author, publication year, 
study size, and duration of follow- up), study population 
information (number of patients for each study, per-
centage of female population, and age), risk factors, 
such as smoking, hypertension, hyperlipidemia, and 
diabetes mellitus, method of CFR determination, out-
comes using raw data and expressed as crude event 
rates, and adjusted time- to- event data, expressed as 
hazard ratios (HRs) that dichotomized CFR as normal 
or abnormal, if available. If results were presented for 
>1 time point, the latest results were extracted. Studies 
reporting the HR using CFR as a continuous variable 
were not included. For studies that reported HRs for 
subgroups, but not for the overall cohort, the HRs and 
95% CIs for each subgroup were extracted. When rel-
evant information was not included in the article, the 
authors were contacted to obtain the data.
Outcomes
The primary outcome was all- cause mortality (or car-
diac death or cardiovascular death if all- cause mortality 
was not provided). The secondary outcome of interest 
was MACE, including cardiac or cardiovascular death, 
nonfatal myocardial infarction, coronary revasculariza-
tion, or cardiac hospitalization.
Quality Assessment
Two investigators (M.A.G., D.L.B). assessed the risk of 
bias using the Newcastle- Ottawa Scale20 for cohort 
studies. A quality score was calculated on the basis 
of 3 major components of cohort studies: selection 
of study groups (0–4 points), comparability of study 
groups (0–2 points), and ascertainment of the outcome 
of interest (0–3 points). A higher score represents bet-
ter methodologic quality. Disagreements in quality as-
sessment were resolved by consensus.
Statistical Analysis
A meta- analysis of summary statistics from each 
article was performed using Comprehensive Meta- 
Analysis 2.0 (Biostat, Inc) software. Estimates of 
effect for both all- cause mortality (unless only car-
diac or cardiovascular mortality was reported) and 
MACE were calculated from crude event rates with a 
random- effects model using inverse variance weight-
ing, expressed as odds ratios (ORs) with 95% CIs, 
and presented in forest plots. The random- effects 
model provides more conservative results than a 
fixed- effects model and assumes that each sample 
comes from a different population and that the ef-
fects in these populations may also differ. Estimates 
of time- to- event data for mortality and MACE were 
calculated using a random- effects model and were 
expressed as HRs with 95% CIs. Statistical signifi-
cance was set at P≤0.05 (2 tailed). Heterogeneity was 
assessed by the I2 test. An I2 of <25% is considered 
no statistical heterogeneity, 25% to 50% is consid-
ered as low statistical heterogeneity, 50% to 75% is 
considered as medium statistical heterogeneity, and 
>75% is considered as high statistical heterogeneity. 
Planned sensitivity analyses included the leave- one- 
out analysis as well as stratified analyses to assess 
any potential differences in method of measurement 
of CFR, for angiographic exclusion of obstructive 
CAD compared with exclusion based on lack of is-
chemia on stress testing, and for different numerical 
definitions of abnormal CFR. Because the number of 
studies was <10 for both mortality and MACE end 
points, a funnel plot assessment for publication bias 
was not performed as the power of the tests is too 
low to distinguish chance from real asymmetry.21
RESULTS
Study Selection and Characteristics
The electronic search identified 3613 citations that 
were screened by reviewing the title and abstract. A 
total of 70 articles were assessed in full text and 11 
studies were included in the meta- analysis (Figure 1). 
For the calculation of ORs for mortality, 8 articles were 
included in the meta- analysis.16,22–28 For the calculation 
of ORs for MACE, 9 articles were included in the meta- 
analysis.16,23,25–31Characteristics of included studies 
are presented in Table 1.
The 8 articles that reported mortality enrolled 6631 
patients, of whom 1970 had CMD (30%). CFR was 
measured invasively in 2 studies, by PET in 3 studies, 
and by transthoracic Doppler echocardiography of the 
left anterior descending coronary artery in 3 studies. 
Most patients were men (52%), and the mean age of 
subjects ranged from 51 to 67 years.
The 9 articles that reported MACE enrolled 5189 
patients, of whom 1447 had CMD (28%). CFR was 
measured invasively in 1 study, by PET in 4 studies, 
and by transthoracic Doppler echocardiography of the 
left anterior descending coronary artery in 4 studies. 
Most patients were women (52%), and the mean age 
ranged from 51 to 67 years. Characteristics of patients 
included in each study are presented in Table 2. We 
evaluated each study using the Newcastle- Ottawa 
Scale quality assessment criteria for cohort studies. 
Study quality is presented in Table S1. Of 9 possible 
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Quantitative Results
Of the 6631 patients included in the 8 studies reporting 
mortality, there were a total of 305 deaths. There were 
122 deaths in the 4661 patients without CMD (2.6%) 
and 183 deaths in the 1970 patients with CMD (9.3%). 
Of the 8 studies, 5 reported cardiac or cardiovascular 
mortality only16,23,25–27 and the remaining 3 reported 
all- cause mortality.22,24,28 The median follow- up ranged 
from 19 months to 8.5 years. The OR for mortality in 
patients with CMD compared with those without CMD 
was 3.93 (95% CI, 2.91–5.30; P<0.001; I2=11.7%) 
(Figure 2A). Three studies presented adjusted HRs for 
mortality.16,23,24 The summary HR for mortality among 
patients with CMD was 3.62 (95% CI, 2.45–5.35; 
P<0.001; I2=17.2%) (Figure 2B).
A total of 5189 patients were included in the 9 stud-
ies that reported MACE, with 412 events reported. 
There were 167 events in the 3742 patients with nor-
mal coronary microvascular function (4.5%) and 245 
events in the 1447 patients with CMD (16.9%). The me-
dian follow- up ranged from 1 to 8 years. The OR for 
MACE in patients with CMD compared with those with 
normal coronary microvascular function was 5.16 (95% 
CI, 2.81–9.47; P<0.001; I2=82.5%) (Figure  3A). Seven 
studies presented adjusted HRs for MACE.23,25–27,29–
31 The summary HR for MACE among patients with 
CMD was 4.42 (95% CI, 2.79–7.01; P<0.001; I2=75.2%) 
(Figure 3B).
Sensitivity Analysis
Sensitivity analyses to assess the potential impact of 
qualitative differences in study design and patient se-
lection showed that exclusion of any single trial from 
the analyses for mortality or MACE did not alter the 
overall findings of the analysis and demonstrated that 
no individual study had a disproportionate influence 
on between- study heterogeneity. Likewise, the over-
all findings were not modified by an analysis stratified 
by method of CFR measurement, use of angiography 
to exclude obstructive CAD, or definition of abnormal 
CFR (data not shown).
DISCUSSION
In this systematic review and meta- analysis of >5000 
patients with suspected ischemia, nonobstructive epi-
cardial CAD on coronary angiography, or absence of 
myocardial ischemia on stress testing, ≈30% of pa-
tients, equally divided between men and women, had 
abnormally reduced CFR diagnostic of CMD. In these 
patients, we observed a nearly 4- fold higher mortality 
Table 1. Characteristics of Included Studies
Author and Year
No. of 







Marks et al,22 2004 168 Intracoronary CFR 
Doppler flow wire
Death 8.5 3.0
Herzog et al,23 2009 103 Adenosine  
13N–ammonia PET
Cardiac death, nonfatal MI, cardiac 
hospitalization, PCI/CABG
5.5 2.0
Cortigiani et al,29 2010 1660 Dipyridamole stress 
TTE (LAD)
Nonfatal STEMI, NSTEMI, coronary 
revascularization
1.6 2.0
Ziadi et al,30 2011 414 Dipyridamole 
rubidium- 82 PET
Cardiac death, MI, PCI/CABG, cardiac 
hospitalization
1.1 2.0
Cortigiani et al,24 2012 3548 Dipyridamole stress 
TTE (LAD)
Death 1.6 2.0
Lowenstein et al,25 2014 651 Dobutamine or 
dipyridamole stress 
TTE (LAD)
Cardiovascular death, AMI, PCI/CABG 2.9 2.0
Murthy et al,16 2014 1218 Vasodilator rubidium- 
82 PET
Cardiovascular death, AMI, PCI/CABG, 
hospitalization for CHF
1.3 2.0
Dikic et al,31 2015 200 Adenosine stress TTE 
(LAD)
Cardiovascular death, stroke, AMI, unstable 
angina, PCI/CABG
1.2 2.0
Gan et al,26 2017 233 Adenosine stress TTE 
(LAD)
Cardiovascular death, AMI, PCI/CABG 4.5 2.0
Lee et al,27 2018 631 Intracoronary CFR 
guide wire
Cardiac death, vessel- oriented composite 
outcomes (vessel- related death, MI, PCI)
5.1 2.0
Monroy- Gonzalez et al,28 
2019
79 Vasodilator  
13N–ammonia PET
All- cause mortality, hospitalization attributable 
to heart failure, late revascularization
8 2.0
13N indicates nitrogen- 13; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CFR, coronary flow reserve; CHF, congestive heart 
failure; LAD, left anterior descending; MI, myocardial infarction; NSTEMI, non–ST- segment–elevation MI; PCI, percutaneous coronary intervention; PET, positron 
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and a 5- fold increase in MACE among individuals with 
CMD compared with those with normal coronary mi-
crovascular function. CMD was not simply a marker for 
other atherogenic risk factors as synthesis of covariate- 
adjusted time- to- event data showed similar increases 
in HRs for mortality and MACE. The increased risk as-
sociated with CMD was similar across 9 countries on 4 
continents, different patient populations, and regardless 
of the modality used to detect it, including invasive as-
sessment during coronary angiography or noninvasive 
testing with PET scans or Doppler echocardiography.
Although CMD is scarcely mentioned in the 
American College of Cardiology/American Heart 
Association guideline for stable ischemic heart 
disease, with no recommendations provided for 
diagnosis or treatment,32 it is not uncommon. 
Approximately 4 million Americans receive a new di-
agnosis of angina annually.33,34 Up to 40% of these 
patients are found to have nonobstructive CAD35 
and 30% to 70% of such patients, equating to from 
≈500 000 to 1 million Americans, have been demon-
strated to have CMD.36 Unfortunately, stress testing 
and computed tomography coronary angiography, 
both of which are recommended in various guide-
lines37,38 for the evaluation of patients with symp-
















Overall 65 52 21 85 N/A N/A
Normal CFR 60 53 15 82 N/A N/A
Abnormal CFR 73 51 33 88 N/A N/A
Herzog 200923
Overall 31 60 18 60 59 42
Cortigiani 201029
Overall 55 63 19 63 46 25
Ziadi 201130
Overall 39 64 29 68 69 64
Cortigiani 201224
Overall 43 66 22 65 54 30
Normal CFR 44 64 19 64 52 30
Abnormal CFR 35 68 30 72 60 31
Lowenstein 201425
Overall 49 67 13 45 36 12
Normal CFR 49 66 11 44 37 10
Abnormal CFR 51 70 25 52 34 17
Murthy 201416
Overall 67 62 30 73 54 10
Dikic 201531
Overall 55 58 50 70 63 24
Gan 201726
Overall 53 62 12 12 50 49
Normal CFR 43 62 11 13 48 46
Abnormal CFR 61 65 17 13 55 59
Lee 201827
Overall 29 61 29 59 64 18
Normal CFR 28 61 28 58 65 19
Abnormal CFR 33 64 31 61 60 17
Monroy- Gonzalez 201928
Overall 74 51 4 34 28 18
Normal CFR 71 51 4 36 27 9
Abnormal CFR 79 51 3 32 29 29
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intended to diagnose obstructive epicardial CAD, fail 
to detect CMD.
The only prior systematic review on the prognostic 
value of CMD39 included studies of patients with hy-
pertrophic obstructive cardiomyopathy, heart failure, 
and aortic stenosis (type 2 CMD) who were excluded 
in the present analysis that was limited to type 1 CMD. 
Nevertheless, the findings were similar, with a relative 
risk for cardiovascular events of 4.58 in patients with 
CMD for studies measuring CFR using echocardiogra-
phy and 2.44 for studies using PET.
The mechanisms by which CMD leads to ad-
verse outcomes are poorly understood and are 
likely multifactorial. Coronary blood flow, in healthy 
individuals, is regulated at the level of the arteri-
oles to meet myocardial oxygen demand. At rest, 
myocardial oxygen extraction is near maximal and, 
thus, adequate oxygen delivery to the myocardium 
is dependent on coronary blood flow. The coronary 
circulation coordinates the resistance in the micro-
circulation to maintain sufficient coronary blood flow 
throughout the myocardium to prevent myocardial 
ischemia in response to exercise or other stressful 
stimuli. In patients with CMD, the microcirculation is 
unable to adequately respond to stress, leading to 
myocardial ischemia as a result of functional abnor-
malities, such as endothelial and smooth muscle cell 
dysfunction, as well as structural abnormalities, in-
cluding external compression and arteriolar rarefac-
tion.40,41 These mechanisms likely contribute to the 
increased mortality and MACE seen in patients with 
CMD compared with patients with normal coronary 
microvascular function. Furthermore, CMD is usu-
ally associated with mild diffuse atherosclerosis and 
the combination of the 2 may have important clinical 
implications.40 Recent evidence suggests that CMD 
may also play a pivotal role in the development of 
heart failure with preserved ejection fraction.42
Figure 2. Meta- analysis of mortality with and without coronary microvascular dysfunction (CMD).
A, Crude event rates. B, Covariate adjusted time- to- event data. Point estimates of the effect sizes are 
shown for individual studies. Odds ratios or hazard ratios for individual studies are indicated by squares, 
and 95% CIs are indicated by horizontal lines. Pooled estimates and their 95% CIs are represented by 
diamonds. The sizes of the squares and the diamonds are proportional to the weight assigned to the 
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The precise number of patients who undergo test-
ing for CMD is unknown but is likely to be extremely 
low relative to the number of patients with ischemic 
symptoms and nonobstructive CAD, given the belief 
that ruling out obstructive CAD or myocardial ischemia 
identifies low- risk patients, the lack of widespread 
availability of cardiac PET scanners and their myocar-
dial perfusion tracers, lack of familiarity with the use 
of Doppler echocardiography to interrogate the left 
anterior descending coronary artery, and the negative 
impact of invasive measurement of CFR on workflow 
in catheterization laboratories. The significant underdi-
agnosis of CMD has likely dampened the incentive to 
develop diagnostic algorithms and targeted therapies 
and has been a major hurdle even for the validation of 
existing therapeutics for modification of prognosis in 
patients with CMD. Although some existing therapies 
have been shown in small studies to reduce angina or 
improve CFR, specific treatment options that improve 
outcomes of patients with CMD beyond treatment of 
established risk factors, such as hypertension, diabe-
tes mellitus, hyperlipidemia, and smoking cessation, 
are lacking.43
LIMITATIONS
There are several limitations of our study. First, CFR 
is a continuous measure, but most studies dichoto-
mize it using various cutoffs for normal and abnormal. 
Second, caution is appropriate in interpreting the re-
sults of this meta- analysis because the results are 
Figure  3. Meta- analysis of major adverse cardiac events (MACE) with and without coronary 
microvascular dysfunction (CMD).
A, Crude event rates. B, Covariate- adjusted time- to- event data. Point estimates of the effect sizes are 
shown for individual studies. Odds ratios or hazard ratios for individual studies are indicated by squares, 
and 95% CIs are indicated by horizontal lines. Pooled estimates and their 95% CIs are represented by 
diamonds. The sizes of the squares and the diamonds are proportional to the weight assigned to the 
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based on data from observational studies. Although 
our meta- analysis of covariate- adjusted HRs found 
similar magnitudes of increased death and MACE as 
with the unadjusted crude event rates, the possibility 
of unequal distribution of important measured and 
unmeasured prognostic variables remains. Third, 
most of the included studies were performed at re-
ferral centers, which raises the possibility that the pa-
tients studied were not representative of the overall 
population. A more precise estimate of the prognos-
tic implications of CMD will require testing in unse-
lected populations. Fourth, we accepted absence of 
myocardial ischemia on stress testing as a surrogate 
for the absence of obstructive CAD demonstrated by 
coronary angiography. Although patients with CMD 
do not uniformly have ischemia on stress testing be-
cause of the diffuse nature of CMD, some patients 
do, and those patients would have been excluded 
by our selection criteria. Fifth, we cannot exclude the 
possibility that some patients with type 2 CMD were 
included in the cohorts analyzed. Fifth, medical ther-
apies, including β blockers, angiotensin- converting 
enzyme inhibitors, aspirin, and statins, were incon-
sistently reported. Differential use of medical therapy 
could potentially influence outcomes and confound 
the results of the study. Sixth, we were unable to 
perform sex- specific analysis of CMD because of the 
lack of sex- specific frequency and outcomes data 
in the included studies. Finally, we did not include 
emerging technologies, such as magnetic resonance 
imaging as, to our knowledge, there are no magnetic 
resonance imaging studies of the population of in-
terest that have prospectively defined abnormal CFR 
and followed up patients for adverse outcomes.
CONCLUSIONS
This systematic review and meta- analysis of aggregate 
data suggests that patients with isolated CMD, as dem-
onstrated by abnormally reduced CFR, measured in-
vasively or noninvasively, are at substantially increased 
risk of mortality and MACE when compared with those 
without CMD. These results support the need to inte-
grate the totality of the coronary circulation, both mac-
rovascular and microvascular, when conceptualizing 
the pathophysiological characteristics, treatment, and 
prognosis of patients with symptoms of ischemic heart 
disease. The recently reported CorMicA (Coronary 
Microvascular Angina) study demonstrated an improve-
ment in quality of life among angina patients without ob-
structive CAD who underwent vasoreactivity testing and 
were treated on the basis of those results compared with 
standard care.44 Furthermore, multiple knowledge gaps 
exist in our understanding of CMD, which require an in-
tensified research agenda to establish evidence- based 
approaches to the diagnostic evaluation and manage-
ment of patients with CMD.45
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